The mechanism. Wall Street reads Gilead's lenacapavir (Yeztugo) as a clinical slam dunk: a twice-yearly PrEP shot with best-in-class efficacy, priced at roughly $28,218 a year in the U.S. commercial market. But the volume that makes lenacapavir a category-defining franchise — not just a niche PrEP brand — comes from PEPFAR and the Global Fund, which are procuring it at no profit to Gilead for up to 2-3 million people across high-burden countries through 2028. That deal only exists because Congress keeps funding it. PEPFAR has run on one-year reauthorizations since its 2024 lapse, missing multiple deadlines and surviving mostly on continuing appropriations rather than a clean multi-year law. Every appropriations cycle is now a go/no-go vote on whether Gilead's global access strategy — the thing analysts credit with derisking lenacapavir's long-term market position ahead of 2027 generic entry — keeps running at scale.
Who cashes in. GILD is the direct play, but the win is indirect: PEPFAR/Global Fund volume builds real-world adherence data, distribution rails, and treatment-as-prevention momentum that make lenacapavir the default global PrEP standard before generics arrive, protecting the U.S. commercial price umbrella. VRTX benefits from the same appropriations infrastructure in a different disease area — its cystic fibrosis and now gene-therapy platform depends on stable global health financing architecture (Global Fund, multilateral procurement) as it pushes into international reimbursement, and a durable PEPFAR model is a template other diseases point to when lobbying for multilateral drug-access financing. REGN, with its infectious-disease antibody pipeline and government biodefense contracting relationships (BARDA, HHS), benefits generically from Congress staying in the habit of funding large multi-year global health commitments rather than letting the appropriations muscle atrophy.